UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Some remaining challenges regarding multiple endpoints in clinical trials

Statistics in medicine, 2017-12, Vol.36 (28), p.4441-4445

Snapinn, Steven

2017

Volltextzugriff (PDF)

Responder analyses and the assessment of a clinically relevant treatment effect

Trials, 2007-10, Vol.8 (1), p.31-31, Article 31

2007

Volltextzugriff (PDF)

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

The New England journal of medicine, 2001-09, Vol.345 (12), p.861-869

2001

Volltextzugriff (PDF)

A shrinkage estimator for subgroup analysis without the exchangeability assumption

Journal of biopharmaceutical statistics, 2021-11, Vol.31 (6), p.723-735

Snapinn, Steven

2021

Volltextzugriff (PDF)

Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator

The American statistician, 2005-11, Vol.59 (4), p.301-307

2005

Volltextzugriff (PDF)

Noninferiority trials

Trials, 2000-07, Vol.1 (1), Article 19

Snapinn, Steven M

2000

Volltextzugriff (PDF)

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

Annals of internal medicine, 2003-12, Vol.139 (11), p.901

2003

Volltextzugriff (PDF)

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study

Kidney international, 2003-04, Vol.63 (4), p.1499-1507

2003

Volltextzugriff (PDF)

Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy: The RENAAL Study

Clinical journal of the American Society of Nephrology, 2006-07, Vol.1 (4), p.761-767

2006

Volltextzugriff (PDF)

University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (morning panel session)

Clinical trials (London, England), 2018-08, Vol.15 (4), p.335-351

2018

Volltextzugriff (PDF)

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

JAMA : the journal of the American Medical Association, 2004-07, Vol.292 (1), p.55

2004

Volltextzugriff (PDF)

Statins for Secondary Prevention of Cardiovascular Disease: The Right Dose

Pharmacology, 2011-01, Vol.87 (1-2), p.63-69

2011

Volltextzugriff (PDF)

Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study

Diabetes care, 2006-03, Vol.29 (3), p.595-600

2006

Volltextzugriff (PDF)

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Journal of hypertension, 2002-09, Vol.20 (9), p.1879-1886

2002

Volltextzugriff (PDF)

Alternatives for Discounting in the Analysis of Noninferiority Trials

Journal of biopharmaceutical statistics, 2004-12, Vol.14 (2), p.263-273

Snapinn, Steven M.

2004

Volltextzugriff (PDF)

Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: Angiographic results from the PRISM-PLUS Trial (platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms)

Circulation (New York, N.Y.), 1999-10, Vol.100 (15), p.1609-1615

1999

Volltextzugriff (PDF)

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy : The losartan intervention for endpoint (LIFE) reduction in hypertension study

Circulation (New York, N.Y.), 2006-03, Vol.113 (12), p.1588-1596

2006

Volltextzugriff (PDF)

Electrocardiographic Strain Pattern and Prediction of Cardiovascular Morbidity and Mortality in Hypertensive Patients

Hypertension (Dallas, Tex. 1979), 2004-07, Vol.44 (1), p.48-54

2004

Volltextzugriff (PDF)

Comparison of Sample Size Requirements of Randomized and Historically Controlled Trials Based on Calibrated Error Rates

Statistics in biopharmaceutical research, 2023-01, Vol.15 (1), p.69-73

2023

Volltextzugriff (PDF)

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Hypertension (Dallas, Tex. 1979), 2005-01, Vol.45 (1), p.46-52

2005

Volltextzugriff (PDF)

Assessment of futility in clinical trials

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2006-10, Vol.5 (4), p.273-281

2006

Volltextzugriff (PDF)

Treatment effect measures under nonproportional hazards

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2023-01, Vol.22 (1), p.181-193

2023

Volltextzugriff (PDF)

The issue of multiplicity in noninferiority studies

Clinical trials (London, England), 2012-12, Vol.9 (6), p.730-735

2012

Volltextzugriff (PDF)

Benefits and safety of tirofiban among acute coronary Syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in patients limited by Unstable Signs and Symptoms (PRISM-PLUS) trial

Circulation (New York, N.Y.), 2002-05, Vol.105 (20), p.2361-2366

2002

Volltextzugriff (PDF)

Comment on "Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group": The Test Statistic Should Estimate Some Reasonable Measure of Treatment Benefit

Statistics in biopharmaceutical research, 2023-04, Vol.15 (2), p.297-299

2023

Volltextzugriff (PDF)

1 – 25 von 143

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieThe American Journal Of Cardiology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(126)
Mit Volltextzugriff
(132)

Publikationsform

Sprache

Englisch
(143)

Erscheinungsjahr

n.n

Thema

Science & Technology
(86)
Life Sciences & Biomedicine
(82)
Humans
(68)
Mathematics
(37)
Female
(36)
Male
(36)
Biological And Medical Sciences
(35)
Medical Sciences
(35)
Physical Sciences
(35)
Statistics & Probability
(35)
Aged
(33)
Middle Aged
(29)
Clinical Trials
(26)
Mathematical & Computational Biology
(24)
Cardiovascular System & Cardiology
(23)
Losartan - Therapeutic Use
(21)
Hypertension - Drug Therapy
(19)
Pharmacology. Drug Treatments
(19)
Antihypertensive Agents - Therapeutic Use
(18)
Atenolol - Therapeutic Use
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Some remaining challenges regarding multiple endpoints in clinical trials

Responder analyses and the assessment of a clinically relevant treatment effect

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

A shrinkage estimator for subgroup analysis without the exchangeability assumption

Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator

Noninferiority trials

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study

Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy: The RENAAL Study

University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (morning panel session)

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

Statins for Secondary Prevention of Cardiovascular Disease: The Right Dose

Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

Alternatives for Discounting in the Analysis of Noninferiority Trials

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy : The losartan intervention for endpoint (LIFE) reduction in hypertension study

Electrocardiographic Strain Pattern and Prediction of Cardiovascular Morbidity and Mortality in Hypertensive Patients

Comparison of Sample Size Requirements of Randomized and Historically Controlled Trials Based on Calibrated Error Rates

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Assessment of futility in clinical trials

Treatment effect measures under nonproportional hazards

The issue of multiplicity in noninferiority studies

Benefits and safety of tirofiban among acute coronary Syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in patients limited by Unstable Signs and Symptoms (PRISM-PLUS) trial

Comment on "Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group": The Test Statistic Should Estimate Some Reasonable Measure of Treatment Benefit

Aktive Filter

Suchergebnisse filtern